Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

CSL 730 p1 recruiting again.

Lest we forget (January 6, 2017) -

“This collaboration and license agreement with CSL validates our belief that M230 is an exciting recombinant product candidate for potential use in autoimmune indications,” said Craig A. Wheeler....

CSL has agreed to pay Momenta Pharmaceuticals $50 upfront as part of an exclusive research collaboration and global licence agreement to develop and commercialize Fc multimer proteins, including Momenta’s selective Fc receptor immunomodulator, M230, for the treatment of autoimmune disorders. The deal gives CSL an exclusive license to M230, which is anticipated to enter clinical development in 2017. Momenta could also receive another $550 million in clinical, regulatory, and commercialization milestones and retains an option to elect a profit-sharing arrangement, in the case of which it would partly fund global development and commercialization costs in return for a share of U.S. profits, plus ex-U.S. milestones and royalties. Cambridge, MA-based Momenta also has an option to a U.S. co-promotion agreement for M230 and any other product developed through the collaboration. CSL and Momenta expect to start a research collaboration that will focus on developing new Fc multimer proteins originating from either company’s research.

https://www.genengnews.com/topics/drug-discovery/momenta-and-csl-partner-to-develop-fc-multimer-proteins/